ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michael E. Burt
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, B.
Right arrow Articles by Burt, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, B.
Right arrow Articles by Burt, M. E.

Ann Thorac Surg 1996;61:969-972
© 1996 The Society of Thoracic Surgeons


Original Articles: General Thoracic

Isolated Lung Perfusion With Doxorubicin Reduces Cardiac and Host Toxicities Associated With Systemic Administration

Bruce Ng, MS, Steven N. Hochwald, MD, Michael E. Burt, MDPhD

Thoracic Oncology Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York

Accepted for publication November 3, 1995.

Background. For patients with malignant neoplasms metastatic to lung, systemic chemotherapy in doses high enough to achieve significant survival improvement is often limited by host toxicity. Isolated single-lung perfusion offers the advantage of delivering high-dose organ-specific chemotherapy while minimizing systemic toxicity. We compared the cardiac and systemic toxicities associated with intravenous administration versus isolated single-lung perfusion with doxorubicin.

Methods. Thirty-three male Fischer 344 rats weighing 275 to 300 g were randomized into three groups: normal control rats (n = 11), intravenous doxorubicin (7 mg/kg) (n = 11), and isolated left lung perfusion with 320 µg doxorubicin/mL (n = 11). Animals undergoing isolated single-lung perfusion were anesthetized with pentobarbital, intubated, and ventilated, and then had left thoracotomy with cannulation of the pulmonary artery and a pulmonary venotomy; pulmonary artery and vein were clamped proximally. Animals were perfused for 10 minutes at a rate of 0.5 mL/min, followed by a 5 minute rinse with buffered hespan solution. Arteriotomy and venotomy were repaired and circulation was restored. Daily weights were recorded. On day 24, cardiac output was determined in all groups by injection of radiolabeled chromium 51 microspheres.

Results. Animals treated with 7 mg/kg intravenous doxorubicin had a significant weight loss as compared with those treated with isolated lung perfusion (209.2 ± 29.9 g versus 302.3 ± 10.1 g; p < 0.01). Animals treated with isolated single-lung perfusion, after recovering from surgical stress, resumed normal growth pattern. Significant cardiac toxicities were seen in intravenously treated animals; cardiac index (27.4 ± 6.9 versus 39.4 +/6.3 mL•min-1•100 g body weight-1) and heart weights (0.56 ± 0.04 versus 0.88 ± 0.09 g) were reduced in the intravenously treated group as compared with the group treated with isolated single-lung perfusion. In addition, severe hematologic toxicities are associated with intravenous doxorubicin administration.

Conclusions. Intravenous administration of doxorubicin is associated with severe host toxicities, which include weight loss, decreased cardiac function, and hematologic toxicity. Isolated lung perfusion with high-dose doxorubicin is well tolerated and is associated with minimal host toxicity.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
T. Krueger, A. Kuemmerle, S. Andrejevic-Blant, H. Yan, Y. Pan, J.-P. Ballini, W. Klepetko, L. A. Decosterd, R. Stupp, and H.-B. Ris
Antegrade Versus Retrograde Isolated Lung Perfusion: Doxorubicin Uptake and Distribution in a Sarcoma Model
Ann. Thorac. Surg., December 1, 2006; 82(6): 2024 - 2030.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vail, and M. G. Kris
Development of Inhalational Agents for Oncologic Use
J. Clin. Oncol., March 15, 2001; 19(6): 1839 - 1847.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Abolhoda, A. Brooks, S. Nawata, Y. Kaneda, H. Cheng, and M. E. Burt
Isolated Lung Perfusion With Doxorubicin Prolongs Survival in a Rodent Model of Pulmonary Metastases
Ann. Thorac. Surg., July 1, 1997; 64(1): 181 - 184.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.